The Partnership to Improve Patient Care (PIPC) and 34 organizations representing patients, people with disabilities, and older adults submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on the third cycle of the Medicare Drug Price Negotiation Program.
|
PIPC Chairman Tony Coelho recently penned a letter to Nevada Governor Joe Lombardo urging a veto of legislation (AB 259) that would discriminate against patients, people with disabilities. and older adults.
PIPC submitted written testimony in Massachusetts supporting S. 465. S. 465 includes language that would bar the use of the discriminatory quality-adjusted life year (QALY) and similar metrics. The language mirrors the language barring the QALY and similar metrics included in Medicare. The bill includes several other critical patient protections, including requirements for patient centered research and a physical override mechanism.
Texas v. Kennedy is a lawsuit brought by 17 states in federal court in the Northern District of Texas. The lawsuit challenges 2024 regulations from the U.S. Department of Health and Human Services (HHS), claiming that Section 504 of the Rehabilitation Act is unconstitutional.
PIPC Chairman Tony Coelho recently penned a letter to the Maryland Prescription Drug Affordability Board (PDAB) expressing concerns about the PDAB's methodology for setting the Upper Payment Limit (UPL) for selected drugs.
PIPC Urges Legislative Policy Committee to Reject Discriminatory Assessments in the Maryland PDAB2/5/2025
PIPC Chairman Tony Coelho recently submitted a letter to key members of the Maryland Legislative Policy Committee with concerns about legislation that would have serious implications for the patient and disability communities.
PIPC Chairman Tony Coelho submitted a letter to the Oregon Prescription Drug Affordability Board (PDAB) expressing concerns about the Board's use of value assessments that discriminate against patients and people with disabilities.
PIPC submitted a comment letter to the Washington Prescription Drug Affordability Board (PDAB) highlighting the concerns of patients and people with disabilities related to the PDAB’s potential use of discriminatory cost effectiveness analyses.
PIPC recently sent a letter to Senator Bill Ferguson and Delegate Adrianne Jones urging Maryland's Legislative Policy Committee to reject the Prescription Drug Affordability Board's (PDAB) proposed Upper Payment Limit (UPL) plan.
PIPC recently submitted comments to the Oregon Prescription Drug Affordability Board (PDAB) to avoid using studies that rely on discriminatory metrics such as the Quality-Adjusted Life Year (QALY) that have detrimental implications for access to needed care and treatment. The letter also encourages the Oregon PDAB to include patients and people with disabilities throughout its decision-making process.
|
Topics
All
Archives
June 2025
|
